Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Johan W. Smit"'
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Legend - PDF file 66K, Supplementary legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93bd9512e90e8428b684e29321f17aee
https://doi.org/10.1158/1078-0432.22449674
https://doi.org/10.1158/1078-0432.22449674
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).Experimental Design: In this first-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32c02ec5d8571cf1af10f27c04572d3
https://doi.org/10.1158/1078-0432.c.6521723
https://doi.org/10.1158/1078-0432.c.6521723
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Table 2 - PDF file 58K, A summary of PK parameters of quisinostat estimated on day 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5abd1da2e5d291dae19258963466470c
https://doi.org/10.1158/1078-0432.22449668.v1
https://doi.org/10.1158/1078-0432.22449668.v1
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Figure 1a,b - PDF file 45K, Plasma concentration-time profile of 12 mg quisinostat on (a) day 1 and (b) at steady state for MWF treatment schedule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e0706cd6567a0bafdcd4d473361bc5f
https://doi.org/10.1158/1078-0432.22449677
https://doi.org/10.1158/1078-0432.22449677
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Table 1 - PDF file 54K, Number (percentage) of patients exhibiting increased ventricular ectopic activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc3771585f876d8b010770be7fcfcb2
https://doi.org/10.1158/1078-0432.22449671
https://doi.org/10.1158/1078-0432.22449671
Autor:
Juthamas Sukbuntherng, James Jiao, Donna Skee, Joseph Murphy, Jan de Jong, Ronald de Vries, Loeckie de Zwart, Erik Mannaert, Maarten Vliegen, Jan Snoeys, Johan W. Smit, Peter Hellemans
Publikováno v:
British Journal of Clinical Pharmacology. 81:235-245
Aims Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is used in the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia. Ibrutinib undergoes extensive rapid oxidative metabolism mediated by cytochrome P450 3A both at the level of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bff9427ba9481af157e8d11d97e01421
https://doi.org/10.1111/bcp.12787
https://doi.org/10.1111/bcp.12787
Autor:
Xu Steven Xu, Johan W. Smit, Carole A. Ramm, George Wang, David Madrigal, Martha Gonzalez, James Jiao, Gary D. Hammer, Elizabeth O. Buschur, Alice Y. Chang, Richard J. Auchus, Margaret K. Yu
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 99:2763-2770
Chronic supraphysiological glucocorticoid therapy controls the androgen excess of 21-hydroxylase deficiency (21OHD) but contributes to the high prevalence of obesity, glucose intolerance, and reduced bone mass in these patients. Abiraterone acetate (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ac3e4cc219cfce93430bd3402b8fe04
https://doi.org/10.1210/jc.2014-1258
https://doi.org/10.1210/jc.2014-1258
Autor:
Richard D. Baird, Balaji Venugopal, Yusri Elsayed, Richard A Cowan, Nele Fourneau, Ann Forslund, John Camm, Johan W. Smit, Charles Phelps, Johann S. de Bono, Steve Mcclue, Peter Hellemans, Rebecca Kristeleit, Ruth Plummer, T.R. Jeffry Evans, Udai Banerji, Adam Stewart
Publikováno v:
Clinical Cancer Research. 19:4262-4272
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi). Experimental Design: In this first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1144c0a2cfa4158a8f5e41649b231e2d
https://doi.org/10.1158/1078-0432.ccr-13-0312
https://doi.org/10.1158/1078-0432.ccr-13-0312
Autor:
Johan Monbaliu, James Jiao, Caly Chien, Hans Stieltjes, Johan W. Smit, Inneke Wynant, Martha Gonzalez, Carlo Sensenhauser, Jan Snoeys, Apexa Bernard
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 44(10)
Abiraterone acetate, the prodrug of the cytochrome P450 C17 inhibitor abiraterone, plus prednisone is approved for treatment of metastatic castration-resistant prostate cancer. We explored whether abiraterone interacts with drugs metabolized by CYP2C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9608d3f6a24c1ac96f597ba63d156f9
https://pubmed.ncbi.nlm.nih.gov/27504016
https://pubmed.ncbi.nlm.nih.gov/27504016
Autor:
Luca A. Fenu, Eva Hoeben, Achiel Van Peer, Ron Gilissen, Karin Vaarties, Stefan De Buck, Wendy Sanderson, Marjoleen J.M.A Nijsen, Johan W. Smit, Kelly Van Uytsel, Vikash K. Sinha, Claire Mackie
Publikováno v:
Clinical Pharmacokinetics. 50:307-318
Background: It is imperative that new drugs demonstrate adequate pharmacokinetic properties, allowing an optimal safety margin and convenient dosing regimens in clinical practice, which then lead to better patient compliance. Such pharmacokinetic pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759287a16bc429d7831cef21564684ba
https://doi.org/10.2165/11539250-000000000-00000
https://doi.org/10.2165/11539250-000000000-00000